0	10	Monoclonal	monoclonal	JJ
11	27	anti-endothelial	anti-endothelial	JJ
28	32	cell	cell	NN
33	43	antibodies	antibody	NNS
44	48	from	from	IN
49	50	a	a	DT
51	58	patient	patient	NN
59	63	with	with	IN
64	72	Takayasu	Takayasu	NNP
73	82	arteritis	arteritis	NN
83	91	activate	activate	VBP
92	103	endothelial	endothelial	JJ
104	109	cells	cell	NNS
110	114	from	from	IN
115	120	large	large	JJ
121	128	vessels	vessel	NNS
128	129	.	.	.

131	140	OBJECTIVE	objective	NN
140	141	:	:	:
142	144	To	to	TO
145	151	create	create	VB
152	162	monoclonal	monoclonal	JJ
163	179	anti-endothelial	anti-endothelial	JJ
180	184	cell	cell	NN
185	195	antibodies	antibody	NNS
196	197	(	(	(
197	202	mAECA	mAECA	NNP
202	203	)	)	)
204	208	from	from	IN
209	210	a	a	DT
211	218	patient	patient	NN
219	223	with	with	IN
224	232	Takayasu	Takayasu	NNP
233	242	arteritis	arteritis	NN
243	245	to	to	TO
246	254	evaluate	evaluate	VB
255	260	their	their	PRP$
261	268	ability	ability	NN
269	271	to	to	TO
272	280	activate	activate	VB
281	286	human	human	JJ
287	296	umbilical	umbilical	JJ
297	301	vein	vein	NN
302	313	endothelial	endothelial	JJ
314	319	cells	cell	NNS
320	321	(	(	(
321	326	HUVEC	HUVEC	NNP
326	327	)	)	)
327	328	,	,	,
329	332	and	and	CC
333	335	to	to	TO
336	348	characterize	characterize	VB
349	352	the	the	DT
353	362	mechanism	mechanism	NN
363	365	of	of	IN
366	368	EC	EC	NNP
369	379	activation	activation	NN
379	380	.	.	.

381	388	METHODS	methods	NNS
388	389	:	:	:
390	391	A	a	DT
392	397	panel	panel	NN
398	400	of	of	IN
401	406	mAECA	mAECA	NNP
407	410	was	be	VBD
411	420	generated	generate	VBN
421	425	from	from	IN
426	436	peripheral	peripheral	JJ
437	442	blood	blood	NN
443	454	lymphocytes	lymphocyte	NNS
455	457	of	of	IN
458	459	a	a	DT
460	467	patient	patient	NN
468	472	with	with	IN
473	481	Takayasu	Takayasu	NNP
482	491	arteritis	arteritis	NN
491	492	,	,	,
493	498	using	use	VBG
499	511	Epstein-Barr	epstein-barr	JJ
512	517	virus	virus	NN
518	532	transformation	transformation	NN
532	533	.	.	.

534	542	Activity	activity	NN
543	550	against	against	IN
551	564	macrovascular	macrovascular	JJ
565	567	EC	EC	NNP
568	569	(	(	(
569	574	HUVEC	HUVEC	NNP
574	575	)	)	)
576	579	and	and	CC
580	593	microvascular	microvascular	JJ
594	596	EC	EC	NNP
597	598	(	(	(
598	603	human	human	JJ
604	608	bone	bone	NN
609	615	marrow	marrow	NN
616	618	EC	EC	NNP
619	631	immortalized	immortalize	VBN
632	634	by	by	IN
635	639	SV40	SV40	NNP
639	640	)	)	)
641	649	antigens	antigen	NNS
650	653	was	be	VBD
654	662	detected	detect	VBN
663	665	by	by	IN
666	679	enzyme-linked	enzyme-linked	JJ
680	693	immunosorbent	immunosorbent	JJ
694	699	assay	assay	NN
699	700	.	.	.

701	711	Inhibition	Inhibition	NNP
712	719	studies	study	NNS
720	724	were	be	VBD
725	729	used	use	VBN
730	732	to	to	TO
733	739	select	select	VB
740	743	the	the	DT
744	754	monoclonal	monoclonal	JJ
755	765	antibodies	antibody	NNS
766	767	(	(	(
767	772	mAECA	mAECA	NNP
772	773	)	)	)
774	779	which	which	WDT
780	785	share	share	VBP
786	789	the	the	DT
790	794	same	same	JJ
795	797	EC	EC	NNP
798	805	epitope	epitope	NN
806	813	binding	binding	NN
814	825	specificity	specificity	NN
826	828	as	as	IN
829	832	the	the	DT
833	838	total	total	JJ
839	847	IgG-AECA	igg-aeca	NN
848	852	from	from	IN
853	856	the	the	DT
857	865	Takayasu	Takayasu	NNP
866	875	arteritis	arteritis	NN
876	883	patient	patient	NN
883	884	.	.	.

885	888	The	the	DT
889	896	binding	binding	NN
897	899	of	of	IN
900	903	the	the	DT
904	909	mAECA	maeca	NNS
910	912	to	to	TO
913	918	human	human	JJ
919	925	aortic	aortic	JJ
926	928	EC	EC	NNP
929	932	was	be	VBD
933	940	studied	study	VBN
941	943	by	by	IN
944	964	immunohistochemistry	immunohistochemistry	NN
964	965	.	.	.

966	969	The	the	DT
970	979	secretion	secretion	NN
980	986	levels	level	NNS
987	989	of	of	IN
990	1003	interleukin-6	interleukin-6	NN
1004	1005	(	(	(
1005	1009	IL-6	il-6	NN
1009	1010	)	)	)
1011	1014	and	and	CC
1015	1018	von	von	NNP
1019	1029	Willebrand	Willebrand	NNP
1030	1036	factor	factor	NN
1037	1038	(	(	(
1038	1041	vWF	vWF	NNP
1041	1042	)	)	)
1043	1047	were	be	VBD
1048	1058	determined	determine	VBN
1058	1059	,	,	,
1060	1062	to	to	TO
1063	1068	serve	serve	VB
1069	1071	as	as	IN
1072	1079	markers	marker	NNS
1080	1083	for	for	IN
1084	1086	EC	EC	NNP
1087	1097	activation	activation	NN
1097	1098	.	.	.

1099	1102	The	the	DT
1103	1112	activated	activate	VBN
1113	1115	EC	EC	NNP
1116	1120	were	be	VBD
1121	1129	examined	examine	VBN
1130	1133	for	for	IN
1134	1137	the	the	DT
1138	1147	adherence	adherence	NN
1148	1150	of	of	IN
1151	1152	a	a	DT
1153	1162	monocytic	monocytic	JJ
1163	1167	cell	cell	NN
1168	1172	line	line	NN
1173	1174	(	(	(
1174	1178	U937	U937	NNP
1178	1179	)	)	)
1179	1180	,	,	,
1181	1183	as	as	RB
1184	1188	well	well	RB
1189	1191	as	as	IN
1192	1195	for	for	IN
1196	1206	expression	expression	NN
1207	1209	of	of	IN
1210	1218	vascular	vascular	JJ
1219	1223	cell	cell	NN
1224	1232	adhesion	adhesion	NN
1233	1241	molecule	molecule	NN
1242	1243	1	1	CD
1243	1244	,	,	,
1245	1258	intercellular	intercellular	JJ
1259	1267	adhesion	adhesion	NN
1268	1276	molecule	molecule	NN
1277	1278	1	1	CD
1278	1279	,	,	,
1280	1283	and	and	CC
1284	1294	E-selectin	E-selectin	NNP
1294	1295	.	.	.

1296	1298	In	in	IN
1299	1307	addition	addition	NN
1307	1308	,	,	,
1309	1316	nuclear	nuclear	JJ
1317	1325	extracts	extract	NNS
1326	1328	of	of	IN
1329	1332	the	the	DT
1333	1346	mAECA-treated	maeca-treated	JJ
1347	1349	EC	EC	NNP
1350	1354	were	be	VBD
1355	1363	analyzed	analyze	VBN
1364	1367	for	for	IN
1368	1371	the	the	DT
1372	1381	induction	induction	NN
1382	1384	of	of	IN
1385	1398	translocation	translocation	NN
1399	1401	of	of	IN
1402	1409	nuclear	nuclear	JJ
1410	1416	factor	factor	NN
1417	1423	kappaB	kappaB	NNP
1424	1425	(	(	(
1425	1434	NF-kappaB	NF-kappaB	NNP
1434	1435	)	)	)
1435	1436	,	,	,
1437	1442	using	use	VBG
1443	1444	a	a	DT
1445	1453	specific	specific	JJ
1454	1463	NF-kappaB	nf-kappab	NN
1464	1474	oligoprobe	oligoprobe	NN
1475	1477	in	in	IN
1478	1480	an	an	DT
1481	1496	electrophoretic	electrophoretic	JJ
1497	1505	mobility	mobility	NN
1506	1511	shift	shift	NN
1512	1517	assay	assay	NN
1517	1518	.	.	.

1519	1526	RESULTS	results	NNS
1526	1527	:	:	:
1528	1531	Six	six	CD
1532	1537	mAECA	maeca	NNS
1538	1542	were	be	VBD
1543	1551	selected	select	VBN
1551	1552	,	,	,
1553	1556	the	the	DT
1557	1564	mixture	mixture	NN
1565	1567	of	of	IN
1568	1573	which	which	WDT
1574	1582	produced	produce	VBD
1583	1586	100	100	CD
1586	1587	%	%	NN
1588	1598	inhibition	inhibition	NN
1599	1601	of	of	IN
1602	1609	binding	binding	NN
1610	1612	of	of	IN
1613	1616	the	the	DT
1617	1625	original	original	JJ
1626	1629	IgG	igg	NN
1630	1631	(	(	(
1631	1635	from	from	IN
1636	1639	the	the	DT
1640	1647	patient	patient	NN
1648	1652	with	with	IN
1653	1661	Takayasu	Takayasu	NNP
1662	1671	arteritis	arteritis	NN
1671	1672	)	)	)
1673	1675	to	to	TO
1676	1681	HUVEC	HUVEC	NNP
1681	1682	.	.	.

1683	1686	All	all	DT
1687	1692	mAECA	mAECA	NNP
1693	1702	possessed	possess	VBD
1703	1707	high	high	JJ
1708	1716	activity	activity	NN
1717	1724	against	against	IN
1725	1738	macrovascular	macrovascular	JJ
1739	1741	EC	EC	NNP
1741	1742	,	,	,
1743	1746	but	but	CC
1747	1751	none	none	NN
1752	1755	had	have	VBD
1756	1767	significant	significant	JJ
1768	1785	antimicrovascular	antimicrovascular	JJ
1786	1788	EC	EC	NNP
1789	1797	activity	activity	NN
1797	1798	.	.	.

1799	1802	The	the	DT
1803	1808	mAECA	maeca	NNS
1808	1809	,	,	,
1810	1813	but	but	CC
1814	1817	not	not	RB
1818	1824	normal	normal	JJ
1825	1830	human	human	JJ
1831	1834	IgG	igg	NN
1834	1835	,	,	,
1836	1839	had	have	VBD
1840	1850	anti-human	anti-human	JJ
1851	1857	aortic	aortic	JJ
1858	1860	EC	EC	NNP
1861	1869	activity	activity	NN
1869	1870	.	.	.

1871	1875	Four	four	CD
1876	1878	of	of	IN
1879	1882	the	the	DT
1883	1884	6	6	CD
1885	1890	mAECA	maeca	NNS
1891	1900	activated	activate	VBD
1901	1903	EC	EC	NNP
1903	1904	,	,	,
1905	1915	manifested	manifest	VBN
1916	1918	by	by	IN
1919	1928	increased	increase	VBN
1929	1933	IL-6	il-6	NN
1934	1937	and	and	CC
1938	1941	vWF	vwf	NN
1942	1951	secretion	secretion	NN
1951	1952	.	.	.

1953	1956	The	the	DT
1957	1958	4	4	CD
1959	1964	mAECA	maeca	NNS
1965	1972	induced	induce	VBD
1973	1975	EC	EC	NNP
1976	1986	expression	expression	NN
1987	1989	of	of	IN
1990	1998	adhesion	adhesion	NN
1999	2008	molecules	molecule	NNS
2009	2012	and	and	CC
2013	2022	increased	increase	VBN
2023	2031	adhesion	adhesion	NN
2032	2034	of	of	IN
2035	2039	U937	u937	NN
2040	2049	monocytic	monocytic	JJ
2050	2055	cells	cell	NNS
2056	2058	to	to	TO
2059	2061	EC	EC	NNP
2061	2062	.	.	.

2063	2065	In	in	IN
2066	2074	addition	addition	NN
2074	2075	,	,	,
2076	2081	these	these	DT
2082	2087	mAECA	maeca	NNS
2088	2098	stimulated	stimulate	VBD
2099	2102	the	the	DT
2103	2110	nuclear	nuclear	JJ
2111	2124	translocation	translocation	NN
2125	2127	of	of	IN
2128	2131	the	the	DT
2132	2141	NF-kappaB	NF-kappaB	NNP
2142	2155	transcription	transcription	NN
2156	2162	factor	factor	NN
2162	2163	.	.	.

2164	2174	CONCLUSION	conclusion	NN
2174	2175	:	:	:
2176	2179	Our	our	PRP$
2180	2188	findings	finding	NNS
2189	2196	suggest	suggest	VBP
2197	2201	that	that	IN
2202	2206	AECA	AECA	NNP
2207	2210	may	may	MD
2211	2219	directly	directly	RB
2220	2229	stimulate	stimulate	VB
2230	2232	EC	EC	NNP
2233	2235	in	in	IN
2236	2244	Takayasu	Takayasu	NNP
2245	2254	arteritis	arteritis	NN
2255	2262	through	through	IN
2263	2272	elevation	elevation	NN
2273	2275	of	of	IN
2276	2284	adhesion	adhesion	NN
2285	2293	molecule	molecule	NN
2294	2304	expression	expression	NN
2305	2315	associated	associate	VBN
2316	2320	with	with	IN
2321	2330	NF-kappaB	NF-kappaB	NNP
2331	2341	activation	activation	NN
2342	2345	and	and	CC
2346	2354	adhesion	adhesion	NN
2355	2357	of	of	IN
2358	2367	monocytes	monocyte	NNS
2367	2368	,	,	,
2369	2372	and	and	CC
2373	2376	may	may	MD
2377	2386	therefore	therefore	RB
2387	2391	play	play	VB
2392	2393	a	a	DT
2394	2404	pathogenic	pathogenic	JJ
2405	2409	role	role	NN
2410	2412	in	in	IN
2413	2416	the	the	DT
2417	2428	development	development	NN
2429	2431	of	of	IN
2432	2435	the	the	DT
2436	2448	vasculopathy	vasculopathy	NN
2449	2451	in	in	IN
2452	2460	Takayasu	Takayasu	NNP
2461	2470	arteritis	arteritis	NN
2470	2471	.	.	.